Literature DB >> 31120821

Heart Failure With Preserved Ejection Fraction In Perspective.

Marc A Pfeffer1, Amil M Shah1, Barry A Borlaug2.   

Abstract

Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.

Entities:  

Keywords:  clinical trials, phase III; epidemiology; heart failure; heart failure, diastolic

Mesh:

Substances:

Year:  2019        PMID: 31120821      PMCID: PMC6534165          DOI: 10.1161/CIRCRESAHA.119.313572

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  213 in total

1.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors:  B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

2.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

Authors:  K Swedberg; M Pfeffer; C Granger; P Held; J McMurray; G Ohlin; B Olofsson; J Ostergren; S Yusuf
Journal:  J Card Fail       Date:  1999-09       Impact factor: 5.712

3.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort.

Authors:  R S Vasan; M G Larson; E J Benjamin; J C Evans; C K Reiss; D Levy
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

4.  The pathogenesis of acute pulmonary edema associated with hypertension.

Authors:  S K Gandhi; J C Powers; A M Nomeir; K Fowle; D W Kitzman; K M Rankin; W C Little
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

5.  Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving >18 000 patients.

Authors:  L Cronin; S R Mehta; F Zhao; J Pogue; A Budaj; D Hunt; S Yusuf
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

6.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study.

Authors:  R B Devereux; M J Roman; J E Liu; T K Welty; E T Lee; R Rodeheffer; R R Fabsitz; B V Howard
Journal:  Am J Cardiol       Date:  2000-11-15       Impact factor: 2.778

9.  Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study.

Authors:  D W Kitzman; J M Gardin; J S Gottdiener; A Arnold; R Boineau; G Aurigemma; E K Marino; M Lyles; M Cushman; P L Enright
Journal:  Am J Cardiol       Date:  2001-02-15       Impact factor: 2.778

10.  Racial differences in the outcome of left ventricular dysfunction.

Authors:  D L Dries; D V Exner; B J Gersh; H A Cooper; P E Carson; M J Domanski
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

View more
  146 in total

Review 1.  Targeting Age-Related Pathways in Heart Failure.

Authors:  Haobo Li; Margaret H Hastings; James Rhee; Lena E Trager; Jason D Roh; Anthony Rosenzweig
Journal:  Circ Res       Date:  2020-02-13       Impact factor: 17.367

2.  Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Aaron D Jones; Gregory D Lewis; Sanjiv J Shah; Omar F Abouezzedine; Marat Fudim; Brooke Alhanti; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug
Journal:  J Card Fail       Date:  2020-08-19       Impact factor: 5.712

3.  Response by Pfeffer et al to Letter Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective".

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-08-01       Impact factor: 17.367

4.  Coding proposal on phenotyping heart failure with preserved ejection fraction: A practical tool for facilitating etiology-oriented therapy.

Authors:  Junbo Ge
Journal:  Cardiol J       Date:  2020       Impact factor: 2.737

5.  Letter by Nikolova et al Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective".

Authors:  Andriana P Nikolova; TingTing Hong; Robin M Shaw
Journal:  Circ Res       Date:  2019-08-01       Impact factor: 17.367

6.  Pulmonary Vascular Pressures and Gas Exchange Response to Exercise in Heart Failure With Preserved Ejection Fraction.

Authors:  Caitlin C Fermoyle; Glenn M Stewart; Barry A Borlaug; Bruce D Johnson
Journal:  J Card Fail       Date:  2020-08-01       Impact factor: 5.712

7.  Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance.

Authors:  Ambarish Pandey; Muthiah Vaduganathan; Sameer Arora; Arman Qamar; Robert J Mentz; Sanjiv J Shah; Patricia P Chang; Stuart D Russell; Wayne D Rosamond; Melissa C Caughey
Journal:  Circulation       Date:  2020-06-03       Impact factor: 29.690

8.  The clinical characteristics and outcomes of heart failure patient with chronic obstructive pulmonary disease from the Japanese community-based registry.

Authors:  Kensuke Takabayashi; Yuka Terasaki; Miyuki Okuda; Osamu Nakajima; Hitoshi Koito; Tetsuhisa Kitamura; Shouji Kitaguchi; Ryuji Nohara
Journal:  Heart Vessels       Date:  2020-08-07       Impact factor: 2.037

9.  Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction.

Authors:  Mei Methawasin; Joshua Strom; Tomasz Borkowski; Zaynab Hourani; Ray Runyan; John E Smith; Henk Granzier
Journal:  Circ Heart Fail       Date:  2020-05-18       Impact factor: 8.790

Review 10.  Evaluation and management of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.